Abstract
Biologics continue to outperform the global pharma market, driven by premium
priced therapies for conditions that cannot be managed by conventional drugs.
The rapid penetration of novel biologics and the gradual expiry of their
patents will create significant market opportunities for biosimilars
developers through to 2016. In the short term, biosimilar market growth will
be driven by drug classes including erythropoietin, filgrastim, human growth
hormone (hGH) and insulin. ' The Top 10 Biosimilars Players: Positioning,
performance and SWOT analyses' is a new report published by Business Insights
that examines the competitive landscape of the global biosimilars industry.
The latest key issues and evolving business models in the biosimilars market
are identified and the leading companies in this sector are profiled in
detail. This report examines the portfolio sales performances, pipelines and
growth strategies of each of the top 10 biosimilars companies. The
opportunities and threats facing each of these leading players are also
assessed. This report also examines the size, growth and major trends of the
global biosimilars industry, in addition to providing to an assessment of
leading biosimilars companies outside of the top 10.
| 
View Cart
